Brexucabtagene Autoleucel (Tecartus)


 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well patient clinician perspectives, a drug or class.
 The inform non-binding recommendations that help guide decisions Canada’s federal, provincial, territorial governments, with exception Quebec.
 This review assesses brexucabtagene autoleucel (Tecartus) cell suspension in patient-specific single-infusion bag for IV use at target dose 1 × 106 chimeric antigen receptor T-cells per kilogram.
 Indication: For treatment adult patients relapsed refractory B-cell precursor acute lymphoblastic leukemia.